【Can-Fite BioPharma】Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite BioPharma Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing

Partner News

27th Dec,2019 — Can-Fite BioPharma Ltd. issued an announcement, which is summarized as follows:

Can-Fite BioPharma Ltd. announced today that Golan Bitton, CEO of Univo Pharmaceuticals (TASE:UNVO), was elected as a board member to Can-Fite at its recent annual general meeting. In September 2019, Can-Fite BioPharma and Univo Pharmaceutical, a medical cannabis company, entered into a collaboration agreement to co-develop cannabis derived pharmaceutical products based on the platform technology of Can-Fite in the fields of cancer, inflammatory, autoimmune, and metabolic diseases.

Golan Bitton has many years of managerial experience in the Israeli Ministry of Defense. During his tenure there, he Implemented and managed multi-million dollar projects for the Israeli Government. Golan holds a B.A. in Economics and Business Management from Max Stern Academic College and Computer Engineering from Negev University. Golan is the founder of Univo Pharmaceuticals and is considered today as one of the leading worldwide experts in the cannabis arena.

The original website link: